Matteo Molica[Author] - Search Results

Year	Number of Results
2007	1
2008	1
2009	1
2010	1
2011	2
2012	2
2013	3
2014	11
2015	14
2016	10
2017	10
2018	11
2019	10
2020	9
2021	7
2022	4
2023	8
2024	1

1

Maintenance therapy in AML: The past, the present and the future.

Molica M, Breccia M, Foa R, Jabbour E, Kadia TM. Molica M, et al. Am J Hematol. 2019 Nov;94(11):1254-1265. doi: 10.1002/ajh.25620. Epub 2019 Sep 11. Am J Hematol. 2019. PMID: 31429099 Free article. Review.

2

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3-Mutated AML Patients.

Molica M, Perrone S, Rossi M. Molica M, et al. J Clin Med. 2023 May 24;12(11):3647. doi: 10.3390/jcm12113647. J Clin Med. 2023. PMID: 37297842 Free PMC article. Review.

3

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress.

Molica M, Perrone S, Andriola C, Rossi M. Molica M, et al. Cancers (Basel). 2023 Oct 19;15(20):5060. doi: 10.3390/cancers15205060. Cancers (Basel). 2023. PMID: 37894427 Free PMC article. Review.

4

Ponatinib: A Review of Efficacy and Safety.

Massaro F, Molica M, Breccia M. Massaro F, et al. Among authors: molica m. Curr Cancer Drug Targets. 2018;18(9):847-856. doi: 10.2174/1568009617666171002142659. Curr Cancer Drug Targets. 2018. PMID: 28969556 Review.

5

Venetoclax: A Game Changer in the Treatment of Younger AML Patients?

Molica M, Perrone S, Federico V, Alati C, Molica S, Rossi M. Molica M, et al. Cancers (Basel). 2023 Dec 22;16(1):73. doi: 10.3390/cancers16010073. Cancers (Basel). 2023. PMID: 38201501 Free PMC article. Review.

6

How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Perrone S, Ottone T, Zhdanovskaya N, Molica M. Perrone S, et al. Among authors: molica m. Cancer Drug Resist. 2023 Apr 28;6(2):223-238. doi: 10.20517/cdr.2022.130. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37457126 Free PMC article. Review.

7

Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances.

Canichella M, Molica M, Mazzone C, de Fabritiis P. Canichella M, et al. Among authors: molica m. Cancers (Basel). 2023 Dec 20;16(1):42. doi: 10.3390/cancers16010042. Cancers (Basel). 2023. PMID: 38201469 Free PMC article. Review.

8

Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.

Kadia TM, Ravandi F, Molica M, Bataller A, Borthakur G, Daver N, Jabbour E, DiNardo CD, Pemmaraju N, Jain N, Ferrajoli A, Ylimaz M, Bose P, Tidwell RS, Marx KR, Rausch CR, Kanagal-Shamanna R, Wang S, Islam R, Champlin R, Shpall E, Konopleva M, Garcia-Manero G, Kantarjian H. Kadia TM, et al. Among authors: molica m. Am J Hematol. 2023 Nov;98(11):1711-1720. doi: 10.1002/ajh.27054. Epub 2023 Aug 27. Am J Hematol. 2023. PMID: 37635400 Clinical Trial.

9

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Molica M, Mazzone C, Niscola P, de Fabritiis P. Molica M, et al. Front Oncol. 2021 Feb 8;10:610820. doi: 10.3389/fonc.2020.610820. eCollection 2020. Front Oncol. 2021. PMID: 33628731 Free PMC article. Review.

10

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML.

Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P. Molica M, et al. Cancers (Basel). 2022 Jun 8;14(12):2843. doi: 10.3390/cancers14122843. Cancers (Basel). 2022. PMID: 35740508 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

86 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year